NURTURING SUSTAINABLE INNOVATIONS:
A ONE HEALTH APPROACH TO FOOD, HEALTH, AND PLANET
Building upon the success of The British Innovation Fund I, the One Health Fund continues to invest in high-potential companies emerging from the rich ecosystem of University Venturing. With a keen focus on agri-tech, the future of healthcare, climate impact, and alternative protein sectors, the fund is dedicated to supporting ventures where incontrovertible science forms the bedrock of the commercial proposition. This initiative embodies a One Health approach, underscoring the intrinsic connections between Food, Health, and Planet, and striving for sustainable solutions through innovative ventures.
Our pre-seeded portfolio focuses on science and innovation-led technologies in Healthcare, Environment, and Food Production. Each company within this portfolio is driven by compelling scientific advancements and led by a credible management team. The unifying theme is “One Health,” which emphasises the inextricable relationship between Human Health, Food Chain integrity, Food Innovation, and Sustainability.
Advancing the biofuel industry with Modified Black Soldier Fly strains for sustainable bi-products.
Learn MoreRevolutionising patient care by swiftly identifying chemotherapy patients at risk of neutropenic sepsis, chemotherapy patients at risk of neutropenic sepsis, optimising healthcare resources and saving lives.
Learn MoreHarnessing gene-editing technology to enhance livestock farming, promoting animal welfare and resource efficiency.
Learn MoreUtilising a model fusion approach to machine learning for creating diagnostic solutions to human diseases.
Learn MorePioneering animal stem cell solutions to support the global cultivated meat market and promote sustainable food production.
Learn MoreOffering a unique COVID-19 triple antibody testing device to provide real-time immunity analysis.
Learn MoreProviding biodegradable solutions for conventional plastic packaging to combat global plastic pollution.
Learn MoreRevolutionising liver biopsy procedures to enhance safety and acceptance, thereby advancing the understanding and treatment of liver disease.
Harnessing natural bioactives for innovative, eco-friendly solutions in agriculture and healthcare.
Learn MoreFacilitating precise cancer care pathways by connecting patients and doctors to advanced treatment options and clinical trials.
Learn MorePioneering real-time breathing analysis technology to enhance respiratory care and diagnostics.
Learn MoreCambridge-based PragmatIC is a world leader in ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than a human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics.
Learn MoreOxford Science Enterprises (OSE) is an independent, billion-pound investment company founded in 2015 that transforms Oxford University’s cutting-edge research into global solutions. As the largest university incubator in the UK, OSE supports pioneering companies in Life Sciences, Health Tech, and Deep Tech, fostering innovation and significant growth.
Learn MoreViome is a health testing company that uses artificial intelligence (AI) to analyze an individual’s gut biology to gain insights into their health. The service offers personalized food recommendations and made-to-order supplements according to these test results.
ExitBarinthus Biotherapeutics (previoiusly Vaccitech) is a biotechnology company developing vaccines and immunotherapies for infectious diseases, specialising in T-cell immunotherapy. Having developed the Oxford/AstraZeneca vaccine and administering over 2B doses globally, the company was listed on NASDAQ in 2021, reaching a peak valuation of $628m.
ExitTotient is an artificial intelligence-driven drug discovery platform that identifies and harnesses human-derived antibodies from individuals with exceptional immune responses. Totient was acquired by Absci for an undisclosed amount in 2021.
ExitAMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies.
ExitMyDoc is Asia’s leading telemedicine service company. MyDoc’s fully integrated online-to-offline platform streamlines all aspects of primary healthcare into one easy-to-use solution connecting patients to doctors, pharmacies, diagnostic laboratories, clinical-grade health trackers, Fortune 500 and SME employers, and insurers.
ExitCorePower is a UK-based development company, specialising in scalable atomic power technology for ocean transport and heavy industry. In partnership with leading international corporations, CorePower aims to deliver durable zero-emission energy for floating industrial production and deep-sea shipping.
Learn MoreNURTURING SUSTAINABLE INNOVATIONS:
A ONE HEALTH APPROACH TO FOOD, HEALTH, AND PLANET
Building upon the success of The British Innovation Fund I, the Asia Sustainable Impact Fund invests in high-potential late seed and series A companies from Asia or with significant portion of their revenues coming from Asia, emerging from the rich ecosystem of University Venturing. With a keen focus on agri-tech, the future of healthcare, climate impact, and alternative protein sectors, the fund is dedicated to supporting ventures where incontrovertible science forms the bedrock of the commercial proposition. This initiative embodies a One Health approach, underscoring the intrinsic connections between Food, Health, and Planet, and striving for sustainable solutions through innovative ventures.
Advancing the biofuel industry with Modified Black Soldier Fly strains for sustainable bi-products.
Learn MoreHarnessing gene-editing technology to enhance livestock farming, promoting animal welfare and resource efficiency.
Learn MoreOffering a unique COVID-19 triple antibody testing device to provide real-time immunity analysis.
Learn MoreProviding biodegradable solutions for conventional plastic packaging to combat global plastic pollution.
Learn MoreRevolutionising liver biopsy procedures to enhance safety and acceptance, thereby advancing the understanding and treatment of liver disease.
Facilitating precise cancer care pathways by connecting patients and doctors to advanced treatment options and clinical trials.
Learn MorePioneering real-time breathing analysis technology to enhance respiratory care and diagnostics
Learn MoreLeader in plant-based culinary innovation. They have rapidly emerged as a trailblazer in plant-based food technology, leading the way in the alternative protein sector.
Learn MoreFounder & Group CEO
Milltrust International Group
Co-Founder & GROUP MANAGING DIRECTOR
Milltrust International Group
Chief Scientific Officer
Milltrust Ventures
Director & Senior Portfolio Manager
First Estate Capital Management
PORTFOLIO MANAGER
Milltrust Ventures
5 Market Yard Mews
194-204 Bermondsey Street
London SE1 3TQ
United Kingdom
Tel: +44 (0)20 8123 8369
Email: [email protected]
5 Market Yard Mews
194-204 Bermondsey Street
London SE1 3TQ
United Kingdom
Tel: +44 (0)20 8123 8316
Email: [email protected]
Milltrust Ventures
5 Market Yard Mews
194-204 Bermondsey Street
London SE1 3TQ
United Kingdom
Tel: +44 (0)20 8123 8316
Email: [email protected]
77B Tras Street
Singapore 078978
Tel: +65 6225 3052
Fax: +65 6225 3072
Email: [email protected]
77B Tras Street
Singapore 079016
Tel: +65 6225 3052
Email: [email protected]